Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 1

1(25.0%)

N/A

1(25.0%)

4Total

Phase 2(2)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07399210Recruiting

Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics

Role: lead

NCT06846762Recruiting

DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC

Role: lead

NCT06332950Phase 1Not Yet Recruiting

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

Role: lead

NCT04922138Phase 2Unknown

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Role: lead

NCT01217619Phase 2Completed

Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.

Role: lead

NCT02148380Not ApplicableCompleted

Combination of Chemotherapy and Gefitinib as First-line Treatment

Role: lead

All 6 trials loaded